bioAffinity to present CHEST 2026 data on sputum tests for asthma and COPD lung inflammation

bioAffinity Technologies, Inc.

bioAffinity will present poster 3071 at CHEST 2026 on Oct. 20 in Phoenix on sputum-based tests measuring lung inflammation in asthma and COPD.
Research measured targets TSLP, CRLF2, IL4-Rα (CD124) and IL-5, linked to drugs tezepelumab, verkitug, dupilumab and mepolizumab.
Sputum samples came from people with asthma, smokers with/without COPD, a smoker with both COPD and asthma, and healthy individuals; flow cytometry, ELISA and machine learning were used.
CyPath Lung, marketed as an LDT, showed 92% sensitivity, 87% specificity, 88% accuracy and 99% NPV for lung cancer in high-risk patients with nodules under 20 mm.
Global asthma therapeutics market was about $29.7 billion in 2025 and is projected to reach $47.6 billion by 2034.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.